AMAZENTIS
Amazentis, a spin-off of the Swiss Federal Institute of Technology (EPFL) pioneering scientific breakthroughs in cellular health and nutrition, announced today that the peer-reviewed clinical and translational journal Cell Reports Medicine published new clinical results showing the muscle health benefits of the gut microbiome postbiotic Urolithin A. Age-associated muscle decline can start as early as 40 years old and there are currently no effective interventions to counteract it other than exercise.
This milestone study showed that daily intake of Amazentis’ proprietary Urolithin A, Mitopure, significantly improved muscle strength by 12% after four months. These findings further validate Mitopure’s benefits for muscle and mitochondrial health and show it is safe and well tolerated. Mitopure works by supporting the cells’ ability to renew their powerplants, the mitochondria, during the aging process. Muscles have a high demand for energy and there are a very large number of mitochondria in muscle cells.
Previous research showed that Mitopure improved muscle endurance, reduced inflammation, and resulted in healthier mitochondrial function in older adults 65 to 90 years old. This new double-blind, placebo-controlled trial in middle-aged adults 40 to 64 years old (n=88) was conducted in London, Ontario, Canada following approvals from Health Canada and an independent IRB. Participants were randomized to receive daily supplementation with either 500mg, 1,000mg Mitopure or placebo for 4 months. Muscle strength, exercise performance tests and biomarkers of healthy mitochondrial function and inflammation in skeletal muscle biopsies and blood plasma were assessed at baseline, 2 months and 4 months.
- Two measures of skeletal muscle strength were improved in the supplemented groups compared to the placebo group. Muscle strength in the hamstring skeletal muscle was significantly increased in both 500mg (+12%) and 1,000mg groups (+9.8%). Muscle strength during knee flexion was also significantly improved at both 500mg (+10.6%) and 1,000mg doses (+10.5%)
- Clinically meaningful improvements on aerobic endurance (+ 10% in peak oxygen consumption [VO2]), physical performance (+ 33 meters on the 6 min walk test), and power output (+5%) were observed in the 1,000mg group, though not statistically significant
- The blood tests and biopsies showed a significant improvement in biomarkers of healthy mitochondrial function and reduced inflammation
“These results are exciting because this is the first in human demonstration that Urolithin A repairs the mitochondria via mitophagy and can translate to meaningful physiological benefits. Furthermore, the improvement in strength and exercise-performance occurred in the absence of any changes to participants exercise routine,” explained Johan Auwerx, MD, PhD, co-author and Professor at the Swiss Federal Institute of Technology EPFL.
This is an important discovery in longevity and muscle health research. Aging is associated with a decline in mitochondrial function which can lead to reduced exercise capacity, muscle endurance and strength. Urolithin A is the first and only compound that has been clinically shown to improve muscle function by renewing the mitochondria through a potent biological quality control mechanism called mitophagy. By activating this important biological pathway, Mitopure promotes healthy aging and improved muscle health and performance.
“This study further validates the role of mitochondrial health as an important pillar of vitality and shows Mitopure is a first in class nutrient that meaningfully impacts muscle health. We are proud to offer this proprietary form of Urolithin A in our Timeline® brand and inside Nestlé Health Science products,” said Chris Rinsch, CEO and Co-Founder of Amazentis. “We remain committed to pioneering clinically validated products that optimize cellular health with the mission of keeping millions of people healthier for longer”.
In addition, Amazentis also announced that Dr. Eric Verdin has joined the Amazentis scientific advisory board. Dr. Verdin is the president and chief executive officer of the Buck Institute for Research on Aging and he has dedicated his career to studying longevity with the goal of transforming everyone into healthy centenarians.
“Mitochondrial decline is a key hallmark of aging and poor metabolic health. This study is an important milestone and shows that Urolithin A could be a gamechanger in our field.” said. Dr. Eric Verdin.
Doi: 10.1016/j.xcrm.2022.100633
About Amazentis
Amazentis is an innovative life sciences company employing today’s leading research and clinical science to develop the next generation of products targeting mitochondrial health for advanced nutrition. Amazentis has previously published its research on Mitopure™ Urolithin A in top peer reviewed scientific journals including Nature Medicine
(doi:10.1038/nm.4132), Nature Metabolism
(doi: 10.1038/s42255-019-0073-4), JAMA Network Open
(doi:10.1001/jamanetworkopen.2021.44279) and European Journal of Clinical Nutrition
(https://doi.org/10.1038/s41430-021-00950-1
). The company has a global strategic partnership with Nestlé Health Science to expand the health applications of Mitopure™ linked to mitochondrial and cellular health. For more information on Amazentis, please visit www.amazentis.com
.
About Mitopure™
Mitopure™ is a highly pure form of Urolithin A; a bioactive dietary metabolite that is produced by gut bacteria after eating certain foods, such as the pomegranate, though it is difficult for most people to get enough of this specialized nutrient from food alone. Mitopure™ has been shown to improve mitochondrial function by stimulating mitophagy, a process by which aging and damaged mitochondria are cleared from the cell, making way for healthy mitochondria to grow. Mitopure™ has been favorably reviewed by the U.S. Food and Drug Administration (FDA) and deemed safe following a GRAS (generally recognized as safe) filing. Mitopure™ has been extensively evaluated pre-clinically and clinically to support its use in humans for nutritional supplementation. For more information, please visit www.mitopure.com
.
About Timeline®
Timeline® Nutrition is brought to you by the inventors of Mitopure™. This novel, science-first brand was developed by Amazentis on the belief that uncompromising research can unlock a new class of clinically validated nutritional products to optimize cellular health. For more information, please visit www.timelinenutrition.com
.
Related Links
https://www.timelinenutrition.com
https://www.amazentis.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220517005659/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting forbedrer sine organisatoriske udviklingskapaciteter med Omni HR Consulting1.8.2025 19:22:00 CEST | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for menneskelige ressourcer gennem en samarbejdsaftale med Omni HR Consulting, et sydafrikansk konsulentfirma med speciale i løsninger til forretnings- og personaleudvikling. Omni HR Consulting tilbyder en komplet pakke af tjenester, der omfatter organisationsudvikling, præstationsrådgivning, akkrediteret uddannelse, kompetenceudvikling og ledelsesprogrammer gennem sit Business and Leadership Academy. Virksomheden samarbejder med kunderne om at designe og implementere løsninger, der retter sig mod medarbejdernes kompetencer, optimering af resultater og strategisk tilpasning og understøttes af en konsekvent tilgang til projektledelse og overholdelse af sydafrikanske kvalitetsstandarder. "Hos Omni tror vi på, at effektiv udvikling starter med forståelse af konteksten," siger administrerende direktør Lize Moldenhauer. "Vi arbejder tæt sammen med vores kunder for at udvikle skræddersyede løsninger, der skaber målbare fremskridt – hvad ente
DevvStream Deploys Crypto Treasury with Initial Bitcoin and Solana Purchases; Intends to Expand Credit Facility to $300M1.8.2025 16:00:00 CEST | Press release
DevvStream Corp. (Nasdaq: DEVS) (“DevvStream” or the “Company”), a leading carbon management firm specializing in the development, investment, and sale of environmental assets, today announced the initial deployment of its crypto treasury strategy with purchases of Bitcoin ($BTC) and Solana ($SOL), funded by a portion of the first (US)$10 million tranche of its (US)$300 million senior secured convertible notes facility with Helena Global Investment Opportunities 1 Ltd. These acquisitions represent the operational launch of DevvStream’s digital treasury strategy, designed to combine institutional-grade liquidity with blockchain infrastructure. The Company believes Bitcoin provides a liquid, non-correlated store of value and that Solana’s high-throughput network supports the Company’s long-term objectives in, and the industry’s move towards, sustainability-linked tokenization. In parallel, DevvStream announced its intention to increase its existing Equity Line of Credit (ELOC) to (US)$30
BEYOND Launches PASSO, a Sculptural Icon on Palm Jumeirah1.8.2025 15:17:00 CEST | Press release
BEYOND Developments, the forward-thinking real estate brand shaping lifestyle destinations by the sea, has unveiled PASSO, a sculptural waterfront development located on the prestigious West Crescent of Palm Jumeirah. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250801880717/en/ PASSO by BEYOND, a Sculptural Icon on Palm Jumeirah. (Photo: AETOSWire) As BEYOND’s first flagship beyond its masterplan in Dubai Maritime City, PASSO marks a defining milestone in the company’s strategic growth to one of the world’s most iconic and desirable destinations. The project launched with a spectacular Palm Jumeirah event featuring Dubai’s first-ever “screens in the sky” show, a 13-minute performance with over 4,000 drones blending immersive visuals and live stage action. Comprising two sculptural towers, Avita and Bella, PASSO offers 625 residences in a refined mix of layouts. From one-bedroom retreats and two-to-four-bedroom-plus lifest
LevelBlue Completes Acquisition of Aon’s Cybersecurity and IP Litigation Consulting Groups1.8.2025 14:00:00 CEST | Press release
Strategic deal enhances LevelBlue's cybersecurity offerings, solidifying its position as the world’s largest leading independent, pure-play MSSP LevelBlue, a global leader in cloud-based, AI-driven managed security services, today announced the completion of its acquisition of Aon’s (NYSE: AON) Cybersecurity and Intellectual Property (IP) Litigation consulting groups, including the renowned cybersecurity firm, Stroz Friedberg, and Elysium Digital. With this completion the consulting group will operate as Stroz Friedberg, a LevelBlue company. This strategic acquisition adds elite cyber and high-tech IP litigation consulting expertise to the LevelBlue portfolio, which includes a globally recognized platform of approximately 300 technology professionals with deep relationships across Fortune 500 companies, 80 percent of the Am Law 100, and most of the UK’s top 20 law firms. As a result, LevelBlue will significantly fortify its incident response and advisory capabilities, while expanding i
SBC Medical to Announce Q2 2025 Financial Results and Hold Conference Call on August 13, 20251.8.2025 14:00:00 CEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global franchise and provider of services for aesthetic clinics, today announced that it will report its Q2 2025 financial results on Wednesday, August 13, 2025, before the U.S. market opens. The Company will hold a conference call on Wednesday, August 13, 2025 at 8:30 am Eastern Time (or Wednesday, August 13, 2025 at 9:30 pm Japan Time) to discuss the financial results and take questions live. Please register in advance of the conference using the link provided below. https://edge.media-server.com/mmc/p/ukc9sp9j It will automatically direct you to the registration page of “SBC Q2 2025 Financial Results Presentation.” Please follow the steps to enter your registration details, then click “Submit.” Upon registration, you will be able to access the dedicated Conference Call viewing site. In addition to viewing the conference call, this site provides access to information about the speakers as well a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom